Stifel Maintains Buy on Definitive Healthcare, Lowers Price Target to $9.5
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst David Grossman has maintained a Buy rating on Definitive Healthcare (NASDAQ:DH) but lowered the price target from $11 to $9.5. This adjustment reflects a change in valuation but continues to support an optimistic outlook for the company.

May 08, 2024 | 1:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Stifel maintains a Buy rating on Definitive Healthcare but lowers the price target from $11 to $9.5.
While the reduction in the price target could suggest a more cautious view on the stock's short-term price potential, the maintenance of a Buy rating indicates a continued positive outlook on the company's fundamentals. This mixed signal could lead to a neutral short-term impact on the stock price as investors weigh the lowered price target against the ongoing endorsement of the stock's value.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100